Pre-made Aprutumab benchmark antibody ( Whole mAb ADC, anti-FGFR2 therapeutic antibody, Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-031
Pre-Made Aprutumab biosimilar, Whole mAb ADC, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Aprutumab Ixadotin is an antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated to an as of yet unidentified toxin, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-031-1mg | 1mg | Inquiry | ||
GMP-Bios-ab-031-10mg | 10mg | Inquiry | ||
GMP-Bios-ab-031-100mg | 100mg | Inquiry | ||
GMP-Bios-ab-031-xmg | ≥100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Aprutumab biosimilar, Whole mAb ADC, Anti-FGFR2 Antibody: Anti-BBDS/BEK/BFR-1/CD332/CEK3/CFD1/ECT1/JWS/K-SAM/KGFR/TK14/TK25 therapeutic antibody |
INN Name | Aprutumab |
Target | FGFR2 |
Format | Whole mAb ADC |
Derivation | Human |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Lambda |
Highest_Clin_Trial (Jan '20) | Phase-I |
Est. Status | Discontinued |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2016 |
Year Recommended | 2017 |
Companies | Bayer |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Solid tumours |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<